Cost effectiveness of sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase-4 (DPP-4) …
Objective This study aimed to systematically review cost-effectiveness studies of newer
antidiabetic medications. Methods The PubMed/MEDLINE, EMBASE, CINAHL Plus …
antidiabetic medications. Methods The PubMed/MEDLINE, EMBASE, CINAHL Plus …
Cost-effectiveness of newer antidiabetic drugs as second-line treatment for type 2 diabetes: a systematic review
J Zhu, Y Zhou, Q Li, G Wang - Advances in Therapy, 2023 - Springer
Introduction Evidence from cardiovascular outcome trials (CVOTs) for newer antidiabetic
drugs is increasingly influencing revised recommendations for second-line therapy in type 2 …
drugs is increasingly influencing revised recommendations for second-line therapy in type 2 …
The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: an economic evaluation using data from the DECLARE‐TIMI 58 trial
P McEwan, AR Morgan, R Boyce… - Diabetes, Obesity …, 2021 - Wiley Online Library
Aim To undertake a cost‐effectiveness analysis of dapagliflozin in treating high‐risk patients
with type 2 diabetes mellitus (T2DM), using both directly observed events in the DECLARE …
with type 2 diabetes mellitus (T2DM), using both directly observed events in the DECLARE …
Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes
J Geng, H Yu, Y Mao, P Zhang, Y Chen - Pharmacoeconomics, 2015 - Springer
Abstract Background Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of
antidiabetic drugs used for treating type 2 diabetes mellitus. While many studies have …
antidiabetic drugs used for treating type 2 diabetes mellitus. While many studies have …
The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland
A Pelczarska, M Jakubczyk, J Jakubiak-Lasocka… - Atherosclerosis, 2018 - Elsevier
Background and aims Familial hypercholesterolaemia (FH) elevates the cholesterol level
and increases the risk of coronary events and death. Early detection and treatment reduce …
and increases the risk of coronary events and death. Early detection and treatment reduce …
Cost–utility analysis of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn basal insulin as add-on to …
Introduction This study aimed to assess the costs and benefits of three alternative second-
line treatment strategies for Swedish patients with type 2 diabetes mellitus (T2DM) who fail …
line treatment strategies for Swedish patients with type 2 diabetes mellitus (T2DM) who fail …
[HTML][HTML] Adverse drug events in cost-effectiveness models of pharmacological interventions for diabetes, diabetic retinopathy, and diabetic macular edema: a sco** …
M Pesonen, V Jylhä, E Kankaanpää - JBI Evidence Synthesis, 2024 - journals.lww.com
Objective: The objective of this review was to examine the role of adverse drug events
(ADEs) caused by pharmacological interventions in cost-effectiveness models for diabetes …
(ADEs) caused by pharmacological interventions in cost-effectiveness models for diabetes …
How consistent is the relationship between improved glucose control and modelled health outcomes for people with type 2 diabetes mellitus? A systematic review
Background There are an increasing number of studies using simulation models to conduct
cost-effectiveness analyses for type 2 diabetes mellitus. Objective To evaluate the …
cost-effectiveness analyses for type 2 diabetes mellitus. Objective To evaluate the …
Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU
LPH Yang - Drugs, 2012 - Springer
Saxagliptin (Onglyza™) is a dipeptidyl peptidase 4 inhibitor widely approved for the
treatment of type 2 diabetes mellitus. In the EU, saxagliptin is indicated as combination …
treatment of type 2 diabetes mellitus. In the EU, saxagliptin is indicated as combination …
Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus
Background Economic models are considered to be important, as they help evaluate the
long-term impact of diabetes treatment. To date, it appears that no article has reviewed and …
long-term impact of diabetes treatment. To date, it appears that no article has reviewed and …